Media Summary: Website: Twitter: Facebook: LinkedIn: ... In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the ... Breast Cancer Research: Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and ...

Dr Tolaney On The Current - Detailed Analysis & Overview

Website: Twitter: Facebook: LinkedIn: ... In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the ... Breast Cancer Research: Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and ...

Photo Gallery

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer
Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer
Interpreting ASCENT-04 Findings With Dr. Sarah Tolaney
Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer
Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer
Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer
Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer
ESMO25: Sara Tolaney, MD, MPH ASCENT-03 | Dana-Farber Cancer Institute
Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky
Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer
SABCS22: Sara Tolaney, MD, MPH | Dana-Farber Cancer Institute
Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer
Sponsored
Sponsored
View Detailed Profile
Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

Sara M.

Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

Website: https://www.onclive.com Twitter: https://twitter.com/OncLive Facebook: https://www.facebook.com/OncLive/ LinkedIn: ...

Sponsored
Interpreting ASCENT-04 Findings With Dr. Sarah Tolaney

Interpreting ASCENT-04 Findings With Dr. Sarah Tolaney

Dr

Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer

Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer

Sara M.

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

Sara M.

Sponsored
Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

Sara M.

Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer

Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer

Sara M.

ESMO25: Sara Tolaney, MD, MPH ASCENT-03 | Dana-Farber Cancer Institute

ESMO25: Sara Tolaney, MD, MPH ASCENT-03 | Dana-Farber Cancer Institute

Breast Cancer Research at ESMO25:

Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky

Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky

In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the ...

Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer

Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer

Sara M.

SABCS22: Sara Tolaney, MD, MPH | Dana-Farber Cancer Institute

SABCS22: Sara Tolaney, MD, MPH | Dana-Farber Cancer Institute

Breast Cancer Research: Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and ...

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

Sara M.

Dr. Tolaney on the Evolution of Treatment in HER2+ Breast Cancer

Dr. Tolaney on the Evolution of Treatment in HER2+ Breast Cancer

Sara M.